0 42

Cited 0 times in

Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy

 Padmanee Sharma  ;  Joohyuk Sohn  ;  Sang Joon Shin  ;  Do-Youn Oh  ;  Bhumsuk Keam  ;  Hyo Jin Lee  ;  Marco Gizzi  ;  Ewa Kalinka  ;  Filip Y F L de Vos  ;  Dario Ruscica  ;  Salvatore Ferro  ;  Feng Xiao  ;  Paul Baverel  ;  Cecil Chi-Keung Chen  ;  Kobby Asubonteng  ;  Nassim Morsli  ;  Luc Dirix 
 CLINICAL CANCER RESEARCH, Vol.26(1) : 61-70, 2020-01 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized / therapeutic use* ; Carcinoma, Transitional Cell / drug therapy* ; Carcinoma, Transitional Cell / secondary ; Drug Resistance, Neoplasm / drug effects* ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local / drug therapy* ; Neoplasm Recurrence, Local / pathology ; Neoplasm Staging ; Organoplatinum Compounds / pharmacology* ; Patient Safety ; Salvage Therapy* ; Survival Rate ; Treatment Outcome ; Urinary Bladder Neoplasms / drug therapy* ; Urinary Bladder Neoplasms / pathology
Purpose: Patients with advanced urothelial carcinoma who fail platinum-containing chemotherapy (treatment fails) have a poor prognosis and limited treatment options. Recent approvals of immune-checkpoint inhibitors confirmed the value of immunomodulatory therapy in urothelial carcinoma. Tremelimumab is a selective human immunoglobulin G2 (IgG2) monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4 with demonstrated durable response rate in metastatic melanoma. This is the first study to report the efficacy and safety of tremelimumab in urothelial carcinoma. Patients and Methods: We report the results of the urothelial carcinoma cohort from a phase II, open-label, multicenter study of patients with advanced solid tumors (NCT02527434). Patients with locally advanced/metastatic urothelial carcinoma were treated with tremelimumab monotherapy (750 mg via intravenous infusion every 4 weeks for seven cycles, then every 12 weeks for two additional cycles) for up to 12 months or until disease progression, initiation of other anticancer therapy, unacceptable toxicity, or consent withdrawal. Results: In 32 evaluable patients with metastatic urothelial carcinoma, objective response rate was 18.8% (95% confidence interval, 7.2-36.4), including complete response (CR) in 2 (6.3%), and partial response in 4 patients (12.5%). Median duration of response has not been reached. Stable disease of >= 12 months was reported in 1 patient (3.1%), yielding a disease control rate at 12 months of 21.9%. Overall, tremelimumab was generally well tolerated; safety results were consistent with the known safety profile. Conclusions: Tremelimumab monotherapy demonstrated clinical activity and durable responses in patients with metastatic urothelial carcinoma. This study is the first in which CR has been observed with tremelimumab as a single agent in urothelial carcinoma.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Sohn, Joo Hyuk(손주혁) ORCID logo https://orcid.org/0000-0002-2303-2764
Shin, Sang Joon(신상준) ORCID logo https://orcid.org/0000-0001-5350-7241
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.